Gepirone in the treatment of major depression

Journal of Clinical Psychopharmacology

Volumn 10, Issue 3, 1990, Pages 77S-85S

  Jenkins, Stephen W ^a   Robinson, Donald S ^a   Fabre, Louis F ^b   Andary, Joseph J ^a   Messina, Marianne E ^a   Reich, Linda A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Research Testing Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEPIRONE; PLACEBO;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT;

ADULT; AGED; ANTI-ANXIETY AGENTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; MALE; MIDDLE AGE; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0025340625     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-199006001-00014     Document Type: Article

References (15)

1. Rickels K, Amsterdam J, London J, et al. Buspirone in depressed outpatients: a controlled clinical trial. New Clinical Drug Evaluation Unit Program presentation, Key Biscayne, FL, May 30—June 2, 1989.
2. Amsterdam JD, Berwish N, Potter L, et al. Open trial of gepirone in the treatment of major depressive disorder. Clin Ther Res 1987;41:185–93.
3. Cott JM, Kurtz NM, Robinson DS, et al. A 5-HT-1A ligand with both antidepressant and anxiolytic properties. Psychopharmacol Bull 1988;24:164–7.
4. Bristol-Myers Company. Data on file. Pharmaceutical Research & Development Division, Wallingford, CT.
5. Blier P, deMontigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT-1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987;1:470–80.
6. Eison AS, Yocca FD. Reduction in cortical 5-HT-2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol 1985;111:389–92.
7. Giral P, Martin P, Soubrie P, et al. Reversal of helpless behavior in rats by putative 5-HT-1A agonists. Biol Psychiatry 1988;23:237–42.
8. Robinson DS, Alms DR, Shrotriya RC, et al. Serotonergic anxiolytics and treatment of depression. Psychopathology 1989;22(suppl 1):27–36
9. Robinson DS, Roberts DL, Copp JE, et al. Diagnostic and clinical assessment issues in the development and therapeutic evaluation of psychopharmacologic agents. Psychopharmacol Bull 1989;25:9–15.
10. Wieland S, Lucki I. Antidepressant-like effects of 5HT1A agonists. Neuropharmacology of Serotonin Symposium (abstr 100). Presented to the NY Academy of Sciences, New York, July 10–13, 1989.
11. Lee ET. Statistical methods for survival data analysis. Belmont, CA: Wadsworth, 1980:122–56.
12. Keller MB, Shapiro RW, Lavori PW, et al. Relapse in major depressive disorder. Arch Gen Psychiatry 1982;39:911–5.
13. Charney DS, Heninger GR, Sternberg DE, et al. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. Br J Psychiatry 1982;141:377–86.
14. Roy-Byrne PP, Hommer D. Benzodiazepine withdrawal: overview and implications for the treatment of anxiety. Am J Med 1988;84:1041–52.
15. Dilsaver SC, Greden JC. Antidepressant withdrawal phenomena. Biol Psychiatry 1984;19:237–56.